4.24
+8.72%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Aclaris Therapeutics
From its filings with the US Securities and Exchange Commission
Aclaris Therapeutics is based in Wayne, Pennsylvania and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ACRS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $7.8m and a net loss of $64.9m. At that date it held total assets of $160.5m and shareholders' equity of $103.1m.
We are a clinical-stage biopharmaceutical company focused on discovering and developing novel small and large molecule product candidates for immuno-inflammatory diseases. Our proprietary KINect drug discovery platform coupled with our integrated discovery approach to small and large molecules enables us to identify and advance product candidates designed to have superior target affinity, specificity and potency. We are seeking to identify and consummate transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize our novel product candidates.
Bosakitug (ATI-045) is an investigational, novel, humanized anti-TSLP monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. This mechanism prevents immune cells targeted by TSLP from releasing proinflammatory cytokines. Bosakitug has potential best-in-class properties, including a very high affinity to TSLP, very high potency, an extremely low dissociation rate from TSLP leading to long residence time and enhanced neutralization activity, and a half-life that can potentially support an extended dosing interval. The high affinity and low dissociation observed with bosakitug may be the result of unique biparatopic binding to both the N- and C-terminus of TSLP. Bosakitug has the potential to treat a variety of atopic, immunologic and respiratory diseases. We exclusively license global rights (excluding Mainland China, Macau, Hong Kong and Taiwan (“Greater China”)) to bosakitug from Biosion, Inc.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 7 Oct 2015
- Employees
- 69
- Website
- aclaristx.com ↗
- Head office
- 701 LEE ROAD, WAYNE, PA, 19087
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Neal WalkerNon-Executive Chairman of the Board, Chief Executive Officer, Co-Founder, since 2012$1.4m
- Dr. Hugh DavisPresident, Chief Operating Officer, Director, since 2024$1.6m
- Mr. Kevin BalthaserChief Financial Officer$1.1m
- Dr. Roland KolbeckChief Scientific Officer
- Dr. Jesse HallChief Medical Officer
- Mr. James LoeropChief Business Officer$2.3m
- Mr. Christopher MolineauxLead Independent Director$96,067
- Dr. Maxine GowenIndependent Director$70,442
- Mr. William HumphriesIndependent Director$66,567
- Dr. Anand MehraIndependent Director$87,317
- Mr. Vincent MilanoIndependent Director$73,317
- Dr. Andrew SchiffIndependent Director$64,317
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 42
- Environment
- 40
- Social
- 77
- Governance
- 8
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong Research and Development Capabilities: Aclaris Therapeutics Inc has a robust research and development division, enabling them to continuously innovate and develop new products.
- Diverse Portfolio of Products: The company offers a wide range of therapeutic products across various medical conditions, providing a diverse revenue stream.
- Established Brand Presence: Aclaris Therapeutics Inc has built a reputable brand image in the pharmaceutical industry, which attracts both customers and potential investors.
Weaknesses
- Dependency on a Few Key Products: Aclaris Therapeutics Inc relies heavily on a small number of key products for a significant portion of their revenue, making them vulnerable to market fluctuations or patent expirations.
- Limited Global Presence: The company's market reach is primarily limited to certain regions, which restricts the potential for expansion and exposes them to regional economic challenges.
- Compliance and Regulatory Risks: Aclaris Therapeutics Inc operates in a highly regulated industry, and any non-compliance issues or regulatory obstacles could disrupt their operations or delay product approvals.
Opportunities
- Growing Demand for Innovative Therapies: The increasing demand for advanced treatment options presents an opportunity for Aclaris Therapeutics Inc to develop and market new therapies.
- Expansion into Emerging Markets: The company can capitalize on untapped markets in developing countries, offering their products and services to a wider customer base.
- Strategic Partnerships and Collaborations: Forming partnerships with other pharmaceutical companies or research institutions can enhance Aclaris Therapeutics Inc's capabilities and accelerate product development.
Threats
- Intense Competition: Aclaris Therapeutics Inc faces fierce competition from other established pharmaceutical companies, which can adversely impact market share and pricing.
- Intellectual Property Infringement: The risk of patent infringement or unauthorized replication of their products by competitors poses a significant threat to Aclaris Therapeutics Inc's profitability.
- Economic Volatility and Healthcare Reforms: Unpredictable economic conditions and potential changes in healthcare regulations could affect the affordability and accessibility of Aclaris Therapeutics Inc's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.